Hello, everyone, and how are you today? We hope the weekend, which seemed to go by rather quickly, was invigorating. Now, of course, the time has come to resume that routine of meetings and deadlines. In fact, this looks to be a busy week. So yes, we are brewing a mandatory cup of stimulation to get us going. Please join us. Meanwhile, we hope you accomplish much today and, as a reminder, let us know if you hear of anything interesting...
Roche To Pay $230M For Anadys For Hepatitis C Drug (Bloomberg News)
Vivus Resubmits Diet Pill Application To FDA (Sacramento Bee)
Assessing R&D And The Uncertain Pharma Pipeline (The Financial Times)
Merck Ends Osteoporosis Drug Deal With Japan Tobacco (Reuters)
APP Pharma Increases Propofol Production (Pharmaceutical Business Review)
Drugmakers In Canada Agree To Provide More Shortage Info (CTV)
Pharma Is A Fat Target For Deficit Cutting (Reuters)
Twitter Is Home To More Fake Drug Sales (InPharma-Technologist)
China Increases Cash Rewards For Whistleblowers (Global Times)
India Talks To Pharma About Controlling Drug Prices (Hindu Business Line)
Lack Of Lab Space Dogs Delaware Biotechs (Wilmington News Journal)
US CRO Market To Exceed $20B By 2017 (Pharma Times)
EDITOR'S NOTE: Please check this post for updates throughout the morning
steaming coffee thx to dleggett on flickr